PMV Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About PMVP
All events for PMVP
All deals for PMVP
Financial Ratios
Financial Statements
PMVP vs Sector & Peers
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey. Website pmvpharma.com
Headquarters Princeton, NJ, US